Diagnosis and management of superficial bladder cancer

Greenlee, 2001, Cancer statistics, 2001, CA Cancer J Clin, 51, 15, 10.3322/canjclin.51.1.15 Schatte, 2000, Epidemiology of bladder cancer, 282 Lee, 2000, The natural history of bladder cancer; implications for therapy, Urol Clin North Am, 27, 1, 10.1016/S0094-0143(05)70229-9 Heney, 1992, Natural history of superficial bladder cancer: prognostic features and long-term disease course, Urol Clin North Am, 19, 429, 10.1016/S0094-0143(21)00411-0 Silverman, 1989, Occupational risks of bladder cancer in the United States-II: nonwhite men, J Natl Cancer Inst, 81, 1480, 10.1093/jnci/81.19.1480 Silverman, 1989, Occupational risks of bladder cancer in the United States. I. White men, J Natl Cancer Inst, 81, 1472, 10.1093/jnci/81.19.1472 Rehn, 1895, Blasengeschwulste bei Fuchsin-Arbeitern, Arch Clin Chir, 50, 588 Hueper, 1938, Experimental production of bladder tumors in dogs by administration of beta-naphthylamine, J Ind Hyg Toxicol, 20, 40 Lower, 1982, Concepts in causality: chemically induced human urinary bladder cancer, Cancer, 49, 1056, 10.1002/1097-0142(19820301)49:5<1056::AID-CNCR2820490535>3.0.CO;2-I Mommsen, 1985, N-acetyl-transferase phenotypes in the urinary bladder cacinogenisis of a low risk population, Carcinogenisis, 6, 199, 10.1093/carcin/6.2.199 Bartsch, 1990, Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers, J Natl Cancer Inst, 82, 1826, 10.1093/jnci/82.23.1826 Lillienfield, 1956, The association of smoking with cancer of the urinary bladder in humans, Arch Intern Med, 98, 129, 10.1001/archinte.1956.00250260001001 Clavel, 1989, Tobacco and bladder cancer in males: increased risk for inhalers and smokers of black tobacco, Int J Cancer, 44, 605, 10.1002/ijc.2910440408 Hartge, 1987, Changing cigarette habits and bladder cancer risk: a case control study, J Natl Cancer Inst, 78, 1119 Talaska, 1991, Smoking-related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct, Proc Natl Acad Sci U S A, 88, 5350, 10.1073/pnas.88.12.5350 Travis, 1989, Bladder cancer after chemotherapy for non-Hodgkin`s lymphoma, N Engl J Med, 321, 544, 10.1056/NEJM198908243210815 Boice, 1988, Radiation dose and second cancer risk in patients treated for cancer of the cervix, Radiat Res, 115, 3, 10.2307/3577477 Johnstone, 1998, Second primary malignancies in T1-3N0 prostate cancer patients treated with radiation therapy with 10-year follow-up, J Urol, 159, 946, 10.1016/S0022-5347(01)63777-7 Friedell, 1976, Histopathology and classification of urinary bladder carcinoma, Urol Clin North Am, 3, 53, 10.1016/S0094-0143(21)01095-8 Navon, 1997, Screening cytoscopy and survival of spinal cord injured patients with squamous cell cancer of the bladder, J Urol, 17, 2109, 10.1016/S0022-5347(01)64687-1 Young, 2000, Pathology of carcinomas of the urinary bladder, 310 Grignon, 1991, Primary adenocarcinoma of the urinary bladder: a clinicopathologic analysis of 72 cases, Cancer, 67, 2165, 10.1002/1097-0142(19910415)67:8<2165::AID-CNCR2820670827>3.0.CO;2-M Angulo, 1995, Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer, Urology, 45, 47, 10.1016/S0090-4295(95)96490-8 Younes, 1990, The usefulness of the level of the muscularis mucosae in the in the staging of invasive transitional cell carcinoma of the urinary bladder, Cancer, 66, 543, 10.1002/1097-0142(19900801)66:3<543::AID-CNCR2820660323>3.0.CO;2-R Mostofi, 1973 Sobin, 1997 Epstein, 1998, The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasm of the urinary bladder. Bladder Consensus Conference Committee, Am J Surg Pathol, 22, 1435, 10.1097/00000478-199812000-00001 Turner, 1977, Haematuria diagnostic service, BMJ, 2, 29, 10.1136/bmj.2.6078.29 Carson, 1979, Clinical importance of microhematuria, JAMA, 241, 149, 10.1001/jama.241.2.149 Golin, 1980, Asymptomatic microscopic hematuria, J Urol, 124, 389, 10.1016/S0022-5347(17)55461-0 Mohr, 1986, Asymptomatic microhematuria and urologic disease: a population-based study, JAMA, 256, 224, 10.1001/jama.256.2.224 Gray, 2001, Prospective comparison of computed tomography and intravenous pyelography in the initial evaluation of asymptomatic microhematuria, J Urol, 165, 391 Salo, 1985, CT in determining depth of infiltration of bladder tumors, Urol Radiol, 7, 88, 10.1007/BF02926862 Barentsz, 1997, What is new in bladder cancer imaging, Urol Clin North Am, 24, 583, 10.1016/S0094-0143(05)70403-1 Grossman, 1998, New methods for detection of bladder cancer, Semin Urol Oncol, 16, 17 Ramakumar, 1999, Comparison of screening methods in the detection of bladder cancer, J Urol, 161, 388, 10.1016/S0022-5347(01)61899-8 Badalament, 1987, The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma, Cancer, 60, 1423, 10.1002/1097-0142(19871001)60:7<1423::AID-CNCR2820600702>3.0.CO;2-6 Brown, 2000, Urine cytology: is it still the gold standard for screening?, Urol Clin North Am, 27, 25, 10.1016/S0094-0143(05)70231-7 Heney, 1983, Superficial bladder cancer: progression and recurrence, J Urol, 130, 1083, 10.1016/S0022-5347(17)51695-X Murphy, 1984, Urinary cytology and bladder cancer: the cellular features of transitional cell neoplasms, Cancer, 53, 1555, 10.1002/1097-0142(19840401)53:7<1555::AID-CNCR2820530723>3.0.CO;2-G Raab, 1994, Low grade transitional cell carcinoma of the bladder: Cytologic diagnosis by key features as identified by logistic regression analysis, Cancer, 74, 1621, 10.1002/1097-0142(19940901)74:5<1621::AID-CNCR2820740521>3.0.CO;2-E Gregoire, 1997, Diagnostic accuracy of urinary cytology and deoxyribonucleic acid flow cytometry and cytology on bladder washings during follow-up for bladder tumors, J Urol, 157, 1660, 10.1016/S0022-5347(01)64827-4 Soloway, 1999, Editorial: do we have a prostate specific antigen for bladder cancer?, J Urol, 161, 447, 10.1016/S0022-5347(01)61920-7 Sarosdy, 1995, Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer, J Urol, 154, 379, 10.1016/S0022-5347(01)67054-X Leyh, 1997, Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder, Urology, 50, 49, 10.1016/S0090-4295(97)00206-9 Murphy, 1997, The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms, J Urol, 158, 2102, 10.1016/S0022-5347(01)68167-9 Pode, 1999, Noninvasive detection of bladder cancer with the BTA stat test, J Urol, 161, 443, 10.1016/S0022-5347(01)61918-9 Ellis, 1997, Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors, Urology, 50, 882, 10.1016/S0090-4295(97)00508-6 Soloway, 1996, Use of the new tumor marker, urinary NMP22, in the detection of occult or rapidily recurring transitional cell carcinoma of the urinary tract following surgical treatment, J Urol, 156, 363, 10.1016/S0022-5347(01)65851-8 Stampfer, 1998, Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder, J Urol, 159, 394, 10.1016/S0022-5347(01)63930-2 Schmetter, 1997, A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer, J Urol, 158, 801, 10.1016/S0022-5347(01)64321-0 Lokeshwar, 2000, The HA-Haase urine test: a sensitive and specific method for detecting bladder cancer and evaluating its grade, Urol Clin North Am, 27, 53, 10.1016/S0094-0143(05)70234-2 Grossman, 1998, New methods for detection of bladder cancer, Semin Urol Oncol, 16, 17 Kavaler, 1998, Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity, Cancer, 82, 708, 10.1002/(SICI)1097-0142(19980215)82:4<708::AID-CNCR14>3.0.CO;2-1 Bostwick, 1992, Natural history of early bladder cancer, J Cell Biochem, 161, 31, 10.1002/jcb.240501307 Herr, 2000, Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15 year outcome, J Urol, 163, 60, 10.1016/S0022-5347(05)67972-4 Lamm, 1992, Carcinoma in situ, Urol Clin North Am, 19, 499 Riddle, 1976, Flat carcinoma in situ of bladder, Br J Urol, 47, 829, 10.1111/j.1464-410X.1975.tb04064.x Kiemeney, 1994, Displasia in normal looking urothelium increases the risk of tumor progression in primary superficial bladder cancer, Eur J Cancer, 30, 1621, 10.1016/0959-8049(94)E0133-O Althausen, 1976, Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ, J Urol, 116, 575, 10.1016/S0022-5347(17)58916-8 Herr, 1992, Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10 year follow-up, J Urol, 147, 1020, 10.1016/S0022-5347(17)37452-9 Fitzpatrick, 1986, Superficial bladder tumors: the importance of recurrence pattern following initial resection, J Urol, 135, 920, 10.1016/S0022-5347(17)45923-4 Wheeless, 1993, Consensus review of clinical utility of DNA cytometry in bladder cancer, Cytometry, 14, 478, 10.1002/cyto.990140504 Gustafson, 1982, DNA profile and tumor progression in patients with superficial bladder tumors, Urol Res, 10, 13, 10.1007/BF00256518 Tribukait, 1984, Clinical DNA flow cytometry, Med Oncol Tumor Pharmaeother, 1, 211, 10.1007/BF02934525 de Vere White, 1996, Prognostic significance of DNA ploidy in Ta/T1 bladder cancer: a Southwest Oncology Group study, Urol Onc, 2, 27, 10.1016/1078-1439(96)00031-2 Tetu, 1996, Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer, Hum Pathol, 27, 922, 10.1016/S0046-8177(96)90219-1 Stein, 1998, Prognostic markers in bladder cancer: a contemporary review of the literature, J Urol, 160, 645, 10.1016/S0022-5347(01)62747-2 Sarkis, 1993, nuclear overexpression of p53 protien in transitional cell bladder carcinoma: a marker for disease progression, J Natl Cancer Inst, 85, 53, 10.1093/jnci/85.1.53 Olumi, 2000, A critical analysis of the use of p53 as a marker for management of bladder cancer, Urol Clin North Am, 27, 75, 10.1016/S0094-0143(05)70236-6 Sheinfeld, 1992, Blood group antigens in normal and neoplastic urothelium, J Cell Biochem, 161, 50, 10.1002/jcb.240501311 Decenzo, 1975, Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma, J Urol, 114, 874, 10.1016/S0022-5347(17)67163-5 Newman, 1980, Cell surface A,B or O (H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma, J Urol, 124, 27, 10.1016/S0022-5347(17)55275-1 D`Elia, 1982, ABH isoantigens in stage 0 papillary transitional cell carcinoma of the bladder: Correlation with biological behavior, J Urol, 127, 665, 10.1016/S0022-5347(17)53982-8 Limas, 1979, ABH antigens in transitional cell tumors of the urinary bladder-correlation with clinical course, Cancer, 44, 2099, 10.1002/1097-0142(197912)44:6<2099::AID-CNCR2820440621>3.0.CO;2-I Young, 1979, The prognostic value of cell surface antigens in low grade, non-invasive, transitional cell carcinoma of the bladder, J Urol, 122, 462, 10.1016/S0022-5347(17)56462-9 Johnson, 1980, Prediction of bladder tumor invasion with the mixed cell agglutination test, J Urol, 123, 25, 10.1016/S0022-5347(17)55760-2 Sarkis, 1994, Blood group antigen expression in bladder tumors: immunohistochemical study of superficial bladder lesions, J Exp Clin Cancer Res, 13, 139 Cordon-Cardo, 1988, Blood group-related antigens in human urothelium: enhanced expression of precursors, LeX and LeY determinants in urothelial carcinoma, Cancer Res, 48, 4113 Sheinfeld, 1990, Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation, J Urol, 143, 285, 10.1016/S0022-5347(17)39935-4 Sheinfeld, 1992, The Lewis X antigen as a predictor of tumor recurrence in high risk disease-free bladder cancer patients, J Urol, 147, 423A Smith, 1986, Endoscopic applications of laser energy, Urol Clin North Am, 13, 405, 10.1016/S0094-0143(21)00225-1 Hofstetter, 1981, Endoscopic Nd: YAG laser application for destroying bladder tumors, Eur Urol, 7, 278, 10.1159/000473240 Smith, 1992, Laser surgery for transitional-cell carcinoma, Urol Clin North Am, 19, 473, 10.1016/S0094-0143(21)00415-8 Johnson, 1994, Use of the holmium:YAG laser for treatment of superficial bladder carcinoma, Lasers Surg Med, 14, 213, 10.1002/lsm.1900140303 Kelly, 1976, Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder, J Urol, 115, 150, 10.1016/S0022-5347(17)59108-9 Walther, 2000, The role of photodynamic therapy in the treatment of recurrent superficial bladder cancer, Urol Clin North Am, 27, 163, 10.1016/S0094-0143(05)70244-5 Mitchell, 1985, Oxygen dependence of hematoporphyrin derivative-induced photoinactivation of Chinese hamster cells, Cancer Res, 45, 2008 Duque, 2000, An overview of the treatment of superficial bladder cancer, Urol Clin North Am, 27, 125, 10.1016/S0094-0143(05)70240-8 Bouffioux, 1992, Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organization for Research on Treatment of Cancer, randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin, J Urol, 148, 297, 10.1016/S0022-5347(17)36577-1 1994, The effect of intravesical thiotepa on tumor recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer: a further report with long-term follow-up of a Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer, Br J Urol, 73, 632, 10.1111/j.1464-410X.1994.tb07547.x Koontz, 1981, The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder, J Urol, 125, 307, 10.1016/S0022-5347(17)55018-1 Masters, 1996, Thiotepa pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumor, Cancer Chemother Pharmacol, 38, 59, 10.1007/s002800050448 Hollister, 1980, Hematologic effects of intravesical thiotepa therapy for bladder carcinoma, JAMA, 244, 2065, 10.1001/jama.244.18.2065 Thrasher, 1992, Complications of intravesical chemotherapy, Urol Clin North Am, 19, 529, 10.1016/S0094-0143(21)00419-5 Burnand, 1976, Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma, Br J Urol, 48, 55, 10.1111/j.1464-410X.1976.tb02742.x Byar, 1977, Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer, Urology, 10, 556, 10.1016/0090-4295(77)90101-7 Nocks, 1979, A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thiotepa, J Urol, 122, 27, 10.1016/S0022-5347(17)56236-9 Asahi, 1980, The effects of intravesical instillation of thiotepa on the recurrence rate of bladder tumors, Acta Med Okayama, 34, 43 Schulman, 1982, Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: An EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone, Eur Urol, 8, 207, 10.1159/000473519 Zincke, 1983, Influence of thiopeta and doxorubicin instillation at the time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double blind, controlled trial, J Urol, 129, 505, 10.1016/S0022-5347(17)52205-3 Prout, 1983, Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa, J Urol, 130, 677, 10.1016/S0022-5347(17)51400-7 Medical Research Council Working Party on Urological Cancer, London, 1985, The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer: an MRC study, Br J Urol, 57, 680, 10.1111/j.1464-410X.1985.tb07031.x Hirao, 1992, A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer-intravesical thio-TEPA versus oral UFT, Cancer Chemother Pharmacol, 30, 26, 10.1007/BF00686937 Lamm, 1992, Long-term results of intravesical therapy for superficial bladder cancer, Urol Clin North Am, 19, 573, 10.1016/S0094-0143(21)00424-9 Lamm, 1995, Apparent failure of current intravesical chemotherapy prophlaxis to influence the long-term cause of superficial transitional cell carcinoma of the bladder, J Urol, 153, 1444, 10.1016/S0022-5347(01)67427-5 Flamm, 1990, Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer, Eur Urol, 17, 119, 10.1159/000464018 Akaza, 1987, Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer: prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group, Cancer Chemother Pharmacol, 20, 91, 10.1007/BF00262495 Lamm, 1991, A randomized trial of doxorubicin and immunotherapy with Bacillus Calmette-GuÉrin for transitional-cell carcinoma of the bladder, N Engl J Med, 325, 1205, 10.1056/NEJM199110243251703 Niijima, 1983, Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer, Cancer Chemother Pharmacol, 11, 79, 10.1007/BF00256725 Rubben, 1988, Natural history and treatment of low and high risk superficial bladder tumors, J Urol, 139, 283, 10.1016/S0022-5347(17)42387-1 Obata, 1994, Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer, Cancer Chemother Pharmacol, 35, 88, 10.1007/BF00686928 Kurth, 1997, Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and tranurethral resection alone, J Urol, 158, 378, 10.1016/S0022-5347(01)64484-7 Ali-el-Dein, 1997, Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study, J Urol, 158, 68, 10.1097/00005392-199707000-00018 Colver, 1990, Dermatitis due to intravesical mitomycin C: a delayed type hypersensitivity reaction?, Br J Dermatol, 122, 217, 10.1111/j.1365-2133.1990.tb08268.x Huland, 1983, Mitomycin instillation to prevent recurrence of superficial bladder carcinoma: Results of a controlled prospective study in 58 patients, Eur Urol, 9, 84, 10.1159/000474054 Kim, 1989, Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor, J Urol, 141, 1337, 10.1016/S0022-5347(17)41300-0 Tolley, 1996, The effect of intravesical mitomycin on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow-up, J Urol, 155, 1233, 10.1016/S0022-5347(01)66226-8 Krege, 1996, A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-GuÉrin, J Urol, 156, 962, 10.1016/S0022-5347(01)65673-8 Solsona, 1999, Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short- and long-term follow-up, J Urol, 161, 1120, 10.1016/S0022-5347(01)61606-9 Soloway, 1980, The management of superficial bladder cancer, Cancer, 45, 1856, 10.1002/cncr.1980.45.s7.1856 Schwaibold, 1994, Long-term results of intravesical prevention of recurrence with mitomycin C and Adriamycin in patients with superficial bladder cancer, Urologe A, 33, 479 Kurth, 1991, Phase 12study of intravesical epirubicin in patients with carcinoma in situ of the bladder, J Urol, 146, 1508, 10.1016/S0022-5347(17)38152-1 Oosterlinck, 1993, A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single-stage Ta, T1 papillary carcinoma of the bladder, J Urol, 149, 749, 10.1016/S0022-5347(17)36198-0 Melekos, 1993, Intravesical 4′-epidoxorubicin (epirubicin) versus bacillus Calmette-GuÉrin: a controlled prospective study on the prophylaxis of superficial bladder cancer, Cancer, 72, 1749, 10.1002/1097-0142(19930901)72:5<1749::AID-CNCR2820720539>3.0.CO;2-8 Raitanen, 1995, A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder: Finnish Multicentre Study Group, Br J Urol, 76, 697, 10.1111/j.1464-410X.1995.tb00759.x Igawa, 1996, Intravesical instillation of epirubicin: effect on tumor recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour, Br J Urol, 77, 358, 10.1046/j.1464-410X.1996.08486.x Ali-el-dein, 1997, Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study, Br J Urol, 79, 731, 10.1046/j.1464-410X.1997.00142.x Eto, 1994, Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial, Cancer Chemother Pharmacol, 35, 46, 10.1007/BF00686919 Okimura, 1998, A randomized study of short versus long-term intravesical epirubicin instillation for superficial bladder cancer, Eur Urol, 33, 285, 10.1159/000019581 Kurth, 1997, Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a Euopean Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone, J Urol, 158, 378, 10.1016/S0022-5347(01)64484-7 Pawinski, 1996, A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 Bladder Cancer, J Urol, 156, 1934, 10.1016/S0022-5347(01)65396-5 Mathe, 1969, Active immunotherapy for acute lymphoblastic leukaemia, Lancet, 1, 697, 10.1016/S0140-6736(69)92648-8 Nathanson, 1974, Use of BCG in the treatment of human neoplasms: a review, Semin Oncol, 1, 337 Coe, 1966, Extracutaneous delayed hypersensitivity, particularly in the guinea pig bladder, J Immunol, 10, 127 Morales, 1976, Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors, J Urol, 116, 180, 10.1016/S0022-5347(17)58737-6 Ratliff, 1991, Strategy for improving therapy of superficial bladder cancer, World J Urol, 9, 95, 10.1007/BF00184040 Lattime, 1992, Murine bladder carcinoma cells present antigen to BCG specific CD4+ T-cells, Cancer Res, 52, 4286 Ratliff, 1993, T-cell subsets required for intravesical BCG immunotherapy for bladder cancer, J Urol, 150, 1018, 10.1016/S0022-5347(17)35678-1 Marinez-Pineiro, 1995, Improving the safety of BCG immunotherapy by dose reduction, Eur Urol, 27, 13, 10.1159/000475203 Morales, 1992, Dose response to bacillus Calmette-GuÉrin in the treatment of superficial bladder cancer, J Urol, 147, 1256, 10.1016/S0022-5347(17)37532-8 Zlotta, 1997, Evolution and clinical significance of the T-cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-GuÉrin during intravesical treatment of superficial bladder cancer, J Urol, 157, 492, 10.1016/S0022-5347(01)65185-1 de Reijke, 1996, Urinary cytokines during intravesical bacillus Calmette-GuÉrin therapy for superficial bladder cancer, J Urol, 155, 488, 10.1016/S0022-5347(01)66424-3 Lamm, 2000, Maintenance bacillus Calmette-GuÉrin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study, J Urol, 163, 1124, 10.1016/S0022-5347(05)67707-5 Kavoussi, 1988, Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors, J Urol, 139, 935, 10.1016/S0022-5347(17)42722-4 Catalona, 1987, Risks and benefits of repeated courses of intravesical bacillus Calmette-GuÉrin therapy for superficial bladder cancer, J Urol, 137, 220, 10.1016/S0022-5347(17)43959-0 Haaff, 1986, Two courses of intravesical bacillus Calmette-GuÉrin for transitional cell carcinoma of the bladder, J Urol, 136, 820, 10.1016/S0022-5347(17)45091-9 Lamm, 1985, Bacillus Calmette-GuÉrin immunotherapy for bladder cancer, J Urol, 134, 40, 10.1016/S0022-5347(17)46972-2 Herr, 1985, Experience with intravesical bacillus Calmette-GuÉrin therapy of superficial bladder tumors, Urology, 25, 119, 10.1016/0090-4295(85)90525-4 Herr, 1986, Long-term effect of intravesical bacillus Calmette-GuÉrin on flat carcinoma in situ of the bladder, J Urol, 135, 265, 10.1016/S0022-5347(17)45604-7 Pagano, 1991, A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: Is it effective?, J Urol, 146, 32, 10.1016/S0022-5347(17)37707-8 Lamm, 1992, Carcinoma in situ, Urol Clin North Am, 19, 499 Mori, 1986, A trial of bacillus Calmette-GuÉrin versus adriamycin in superficial bladder cancer: a Southwest Oncoclogy Group Study, Urol Int, 41, 254, 10.1159/000281212 Brosman, 1985, The use of bacillus Calmette-GuÉrin in the therapy of bladder carcinoma in situ, J Urol, 134, 36, 10.1016/S0022-5347(17)46969-2 Herr, 1988, Bacillus Calmette-GuÉrin therapy alters the progression of superficial bladder cancer, J Clin Oncol, 6, 1450, 10.1200/JCO.1988.6.9.1450 Pagano, 1991, A low dose bacillus Calmette-GuÉrin regimen in superficial bladder cancer therapy: is it effective?, J Urol, 146, 32, 10.1016/S0022-5347(17)37707-8 Hudson, 1987, Single course versus maintenance bacillus Calmette-GuÉrin therapy for superficial bladder tumors: a prospective randomized trial, J Urol, 138, 295, 10.1016/S0022-5347(17)43125-9 Badalament, 1987, A Prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-GuÉrin therapy for superficial bladder cancer, J Clin Oncol, 5, 441, 10.1200/JCO.1987.5.3.441 Lamm, 1992, Complications of bacillus Calmette-GuÉrin immunotherapy, Urol Clin North Am, 19, 565, 10.1016/S0094-0143(21)00423-7 Lamm, 1992, Incidence and treatment of complications of bacillus Calmette-GuÉrin in intravesical therapy in superficial bladder cancer, J Urol, 147, 596, 10.1016/S0022-5347(17)37316-0 Olson, 1974, Immunologic reduction of bladder cancer recurrence rate, J Urol, 111, 173, 10.1016/S0022-5347(17)59919-X Jurincic, 1988, Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study, J Urol, 139, 723, 10.1016/S0022-5347(17)42610-3 Flamm, 1994, Topical immunotherapy (KLH) vs chemotherapy (ethoglucid) in prevention of recurrence of superficial bladder cancer: a prospective randomized study, Urologe, 33, 138 Glashan, 1990, A randomized controlled study of intravesical alpha-2b interferon in carcinoma in situ of the bladder, J Urol, 144, 658, 10.1016/S0022-5347(17)39547-2 Stricker, 1996, BCG plus interferon alpha 2b in patients with superficial bladder cancer, Urology, 48, 957, 10.1016/S0090-4295(96)00375-5 O`Donnell, 2000, Co-administration of INF alpha 2b with low dose is effective in patients with superficial bladder cancer who failed BCG, J Urol, 163, 152 Lamm, 1994, Megadose vitamins in bladder cancer: a double-blind clinical trial, J Urol, 151, 21, 10.1016/S0022-5347(17)34863-2 Stein, 2000, Indications for early cystectomy, Sem Urol Oncol, 18, 289 Freeman, 1995, Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction, Cancer, 76, 833, 10.1002/1097-0142(19950901)76:5<833::AID-CNCR2820760518>3.0.CO;2-M Amling, 1994, Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder, J Urol, 151, 31, 10.1016/S0022-5347(17)34865-6 Soloway, 1994, Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy, Cancer, 73, 1926, 10.1002/1097-0142(19940401)73:7<1926::AID-CNCR2820730725>3.0.CO;2-Q Pagano, 1991, Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification, J Urol, 145, 45, 10.1016/S0022-5347(17)38244-7 Ghoneim, 1997, Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1026 cases, J Urol, 158, 393, 10.1016/S0022-5347(01)64487-2 Klan, 1991, Residual tumor discovered in routine transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder, J Urol, 146, 316, 10.1016/S0022-5347(17)37779-0 Pansadoro, 1995, Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results, J Urol, 154, 2054, 10.1016/S0022-5347(01)66692-8 Lebret, 1998, Correlation between p53 over expression and response to bacillus Calmette-GuÉrin therapy in a high risk select population of patients with T1G3 bladder cancer, J Urol, 159, 788, 10.1016/S0022-5347(01)63731-5 Ick, 1997, Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment, Urol, 49, 541, 10.1016/S0090-4295(96)00624-3 Stein, 2000, Indications for early cytectomy, Semin Urol Onc, 18, 289 Malkowicz, 1990, The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2), J Urol, 144, 641, 10.1016/S0022-5347(17)39544-7